不同年龄自发性高血压大鼠心脏AT2R的表达与心肌纤维化

目的观察不同年龄自发性高血压大鼠（SHR）心脏AT2R的表达水平及心肌胶原含量,探讨AT2R在高血压发生、发展过程中的作用。方法 1月龄组（S1）、2月龄组（S2）、3月龄组（S3）、6月龄组（S6）和9月龄组（S9）雄性SHR共五组,每组各6只,各组均有相应月龄的Wistar-Kyoto大鼠（WKY）作对照。采用RBP-I型大鼠血压心率测定仪测量大鼠动脉收缩压（SBP）;放免法（RIA）测定血浆血管紧张素Ⅱ（AngⅡ）;免疫组化染色结合计算机图像分析方法测定心脏AT2R的表达水平,天狼星红胶原染色大鼠的心脏切片。结果 1.SHR SBP随着月龄的增加呈持续上升（P〈0.05）,SHR的SBP均高于相应配对的WKY组（P〈0.05）。2.一个月后SHR血浆AngⅡ浓度均高于S1（P〈0.05）,一个月后SHR血浆AngⅡ浓度均高于相应配对的WKY组（P〈0.05）。3.SHR心脏AT2R免疫染色阳性面积比随着月份的增加而降低,SHR心脏AT2R免疫染色阳性面积比均低于相应配对的WKY组（P﹤0.05）4.SHR心肌中的胶原含量随着月龄的增加而增加。结论 SHR心脏AT2R表达水平比WKY低,并随着年龄的增加而降低。SHR心肌中的胶原含量随着月龄的增加而增加,而WKY无类似趋势。     

不同年龄白发性高血压大鼠肾脏AT1R和AT2R的表达

目的本研究观察不同月龄自发性高血压大鼠（SHR）肾脏ALR和ALR表达,初步探讨AT1R和AT2R在高血压发生、发展过程中的可能作用。方法1月龄组（S1）、2月龄组（S2）、3月龄组（S3）、6月龄组（S6）和9月龄组（墨）雄性SHR共5组,每组各6只,各组均有相应月龄匹配的Wistar-Kyoto大鼠（WKY）作对照。采用RBP-I型大鼠血压心率测定仪测量大鼠尾动脉收缩压（SBP）;放免法测定血浆血管紧张素Ⅱ（AngⅡ）;免疫组化染色结合计算机图像分析方法测定肾脏AT1R和ALR表达水平。结果（1）SHR SBP随着月龄的增加而上升,S6后趋于稳定。（2）1个月后SHR血浆AngⅡ浓度均高于S1（P〈0.05）,而S2、S3、S6和S9之间无明显差别（P〉0.05）;1个月后SHR血浆AngⅡ浓度均高于相应配对的WKY组（P〈0.05）;而WKY各月龄组均无明显差别（P〉0.05）。（3）SHR肾脏AT1R随着月份的增加而增加（P〈0.05）,且高于相应配对的WKY组（P〈0.05）。SHR肾脏ABR随着月份的增加而降低,S6明显降低（P〈0.05）,S6和S9比较无明显差别（P〉0.05）;且均低于相应配对的WKY组（P〈0.05）。WKY各月龄组AT1R和AT2R无明显差别（P〉0.05）。结论SHR肾脏AT1R表达水平比WKY高,并随着年龄的增加而递增;AT2R表达水平比WKY低,并随着年龄的增加而降低。     

感觉神经损伤性盐敏感性高血压大鼠心、肾ACE和ACE2的表达

目的研究肾素-血管紧张素系统（RAS）基因血管紧张素转换酶（ACE）和血管紧张素转换酶2（ACE2）在感觉神经损伤性盐敏感性高血压大鼠心肌和肾脏中的表达情况,探讨ACE、ACE2在盐敏感性高血压发生发展中的作用。方法用乳鼠皮下注射辣椒辣素法建立模型。哺乳期后,大鼠被随机分成4组：对照＋正常盐饮食组（CON-NS）、对照＋高盐饮食组（CON-HS）、辣椒辣素＋正常盐饮食组（CAP-NS）、辣椒辣素＋高盐饮食组（CAP-HS）。四组大鼠分别接受4周不同的处理。至7周龄（分组饲养后第4周）处死大鼠,免疫组化检测大鼠心肌和肾脏ACE和ACE2蛋白的表达,反转录-聚合酶链式反应（RT-PCR）检测大鼠心肌和肾脏ACE和ACE2mRNA的表达。结果①至7周龄（分组饲养后第4周）各组动物体重差异无显著性（P〉0.05）。②各组动物在分组时（0周）鼠尾收缩压差异无显著性（P=0.583）,至7周龄（分组饲养后第4周）,CAP-HS组鼠尾收缩压明显高于其它三组（P〈0.01）。③心肌和肾脏ACE蛋白表达均升高。心肌组织,CAP-HS组与CON-NS比较,P〈0.01,与CON-HS和CAP-NS比较,P〈0.05;肾脏组织,CAP-HS组与其它三组比较,P〈0.01。④心肌和肾脏ACE2蛋白表达均降低。心肌和肾脏组织,CAP-HS组与CON-NS和CAP-NS比较,P〈0.01,与CON-HS比较,P〈0.05。⑤心肌和肾脏ACE mRNA表达均升高。心肌组织,CAP-HS组与CON-NS比较,P〈0.01,与CON-HS和CAP-NS比较,P〈0.05;肾脏组织,CAP-HS组与其它三组比较,P〈0.01。⑥心肌和肾脏ACE2 mRNA表达均降低。心肌和肾脏组织,CAP-HS组与CON-NS和CAP-NS比较,P〈0.01,与CON-HS比较,P〈0.05。结论感觉神经损伤性盐敏感性高血压大鼠心、肾ACE表达升高的同时有ACE2表达的降低,ACE和ACE2表达水平的差异可能与盐敏感性高血压的形成有关。     

易卒中型自发性高血压大鼠中枢和血管中血管紧张素Ⅱ与血压变化关系

工作分析了不同年龄易卒中型自发性高血压大鼠（SHRSP）主动脉中血管紧张素Ⅱ（AⅡ）含量与收缩压（SBP）间的关系。SHRSP的SBP在12及16周龄时均持续上升,20周龄时不再继续上升但维持在高水平;三个年龄组的SHRSP的主动脉AⅡ含量均明显高于同年龄WKY对照鼠,向SHRSP侧脑室灌注巯甲丙脯氨酸四周不仅降低脑区中AⅡ含量,而且具有明显降压效应,同时显著降低主动脉AⅡ含量及血浆、主动脉中去甲肾上腺素和肾上腺素水平,上述结果证实了SHRSP血管中肾素-血管紧张素系统活动的异常与高血压发病学间的密切关系,提示中枢AⅡ可能通过易化外周交感-肾上腺系统活动调节血管中AⅡ水平。     

自发性高血压大鼠心肌肥厚和心肌MAPK、AngⅡ的关系

放免法测定自发性高血压大鼠（ＳＨＲ）血浆及心肌血管紧张素Ⅱ（ＡｎｇⅡ）含量,凝胶内磷酸化法测定心肌丝裂素活化蛋白激酶活性（ＭＡＰＫ）,以心脏重／体重表示心肌肥厚程度。结果表明：与４个月的ＷＫＹ大鼠比较,４个月的ＳＨＲ血浆和心肌组织ＡｎｇⅡ及心肌ＭＡＰＫ活性分别增加了２１８．６％、１０１．２％和１０７．０％,心肌肥大程度严重,其中ＭＡＰＫ活性与心肌肥大程度呈明显正相关。提示４个月ＳＨＲ心肌肥厚可能是     

感觉神经损伤性盐敏感性高血压大鼠心、肾AT1R的表达

目的对感觉神经损伤性盐敏感性高血压大鼠的心肌、肾脏组织中的血管紧张素Ⅱ1型受体（AT1R）在mRNA和受体水平的表达进行检测,探讨AT1R与盐敏感性高血压的关系。方法用乳鼠皮下注射辣椒辣素法建立模型。哺乳期后,大鼠被随机分成4组：对照＋正常盐饮食组（CON-NS）;对照＋高盐饮食组（CON-HS）;辣椒辣素＋正常盐饮食组（CAP-NS）;辣椒辣素＋高盐饮食组（CAP-HS）。至7周龄（分组饲养后第4周）处死大鼠,免疫组织化学方法和反转录-聚合酶链式反应（RT-PCR）分别检测大鼠心肌和肾脏AT1R蛋白,以及AT1 R mRNA的表达。结果①Wistar大鼠在给予不同程度的感觉神经损伤和饲料干预后,各组大鼠尾部收缩压均有明显增加,最终CAP-HS组的尾收缩压显著高于其他三组（P〈0.01）。②免疫组织化学结果显示,CAP-HS组组织有显著的AT1R蛋白表达（P〈0.01）;CON-HS组肾脏、心肌组织中AT1R蛋白表达高于CON-NS组（P〈0.05）。③RT-PCR检测基因表达,与对照组CON-NS相比,实验组CAP-HS的AT1R mRNA表达显著升高（P〈0.01）;CON-HS组肾脏、心肌组织中AT1 R mRNA表达有显著性（P〈0.05）。结论感觉神经损伤性盐敏感性高血压大鼠心、肾AT1R表达升高,AT1R表达水平的差异可能与盐敏感性高血压的形成有关。     

ACE2及其特殊功能

血管紧张素转换酶2（angiotensin—converting enzyme 2,ACE2）是新发现的与血管紧张素转换酶（ACE）相关的羧肽酶,在肾素-血管紧张素系统（rennin-angiotensin system,RAS）中ACE2可以使AngⅡ转换为Ang1-7,从而产生与血管紧张素Ⅱ相反的效应,同时ACE2还可使Ang I转换为Ang1-9。研究发现：ACE2与高血压、SARS以及肾脏、生殖等系统的疾病有着密切的关系。     

自发性高血压大鼠中枢血管紧张素Ⅱ的变化对中枢肾上腺素和去甲肾上腺素含量的影响

自发性高血压大鼠中枢肾上腺能递质含量异常,然其原因仍不清楚。本工作发现:12周龄易卒中型自发性高血压大鼠(SHRSP)脑桥,下丘脑后部、尾核中去甲肾上腺素(NE)含量及延髓、下丘脑前部,下丘脑后部中肾上腺素(E)含量均高于同龄 Wista Kyoto 大鼠(WKY),SHRSP 中枢 AⅡ含量亦明显高于同龄 WKY;向8周龄 SHRSP 和 WKY 侧脑室慢性灌注巯甲丙脯氨酸,不仅降低动脉血压及各脑区AⅡ含量,亦使中枢 NE 及 E 水平下降,但巯甲丙脯氨酸对 SHRSP 的影响远较对 WKY 明显。结果提示:SHRSP 中枢肾上腺能递质含量增加可能与 SHRSP 中枢 AⅡ量含量升高以及 SHRSP 中枢 AⅡ对中枢肾上腺能递质的促释放调节机制明显易化有关。     

肾性和自发性高血压大鼠心肌肥大前后心肌Gαq/11含量的变化

目的 :探讨Gαq/11在不同原因所致心肌肥大中的变化。方法 :两肾一夹肾性高血压大鼠 (RHR)和自发性高血压大鼠(SHR)模型 ,测定动脉血压和心肌肥大指数 ,放免法测定心肌血管紧张素II(AngII)含量 ,免疫印迹法测定心肌Gαq/11含量。 结果 :RHR术后 1周动脉血压、心肌肥大指数及Gαq/11含量与假手术组无差异 ,心肌AngII含量显著升高 (P <0 .0 1) ;术后 8周上述各指标均较假手术组升高。 12周龄SHR动脉血压、心肌肥大指数和AngⅡ含量均较同龄WKY升高 (P均 <0 .0 1) ,但心肌Gαq/11含量却无明显变化 ;4周龄时上述各指标与同龄对照相比均无明显差异。 结论 :Gαq/11在肾性和自发性高血压心肌肥大中有不同变化。     

自发性高血压大鼠中枢血管紧张素Ⅱ的变化对中枢肾上腺素...

The content of norepinephrine (NE) and epinephrine (E) in the brain of spontaneously hypertensive rats has proved abnormal, but the cause remained unknown. It was shown in the recent work that NE content in pons, posterior hypothalamus, nucleus caudatus and E concentration in medulla oblongata, anterior and posterior hypothalamus of 12-week old stroke-prone spontaneously hypertensive rats (SHRSP) were much higher than those of age-matched Wister-Kyoto rats (WKY). SHRSP also showed higher levels of systolic blood pressure (SBP) and brain angiotensin II (A II) than WKY. Intracerebroventricular (icv) perfusion of angiotensin-converting enzyme inhibitor captopril (20 micrograms for each time and three times for each day for four weeks) inhibited the synthesis of brain A II and reduced SBP and NE, E contents in all examined brain areas in SHRSP and WKY. However, the effects of chronically perfused captopril on SBP and brain NE, E levels in SHRSP were much more significant than in WKY. The results indicate that the modulatory effects of central renin-angiotensin system (RAS) on central adrenergic and noradrenergic system might be overactivated in SHRSP, which might partially responsible for the abnormally high levels of NE, E in some of the brain areas of SHRSP.     

钙离子对自发性高血压大鼠（SHR）肠系膜血管床活动的影响

本文以ＳＨＲ为实验组,ＷＫＹ为对照组,以灌流压为血管舒缩的指标,对其离体肠系膜血管床,初步研究了钙离子的稳定作用,实验结果如下：（１）ＳＨＲ与ＷＫＹ相比,对血管活性物质去甲肾上腺素（ＮＡ）和氯化钾（ＫＣＩ）均表现出较高反应性。（２）在ＮＡ（１．７×１０Ｍ）使血管床收缩的基础上,Ｃａ￣（＋＋）（２０ｍＭ）使之明显舒张,ＳＨＲ的舒张程度小干ＷＫＹ约１８．１７％（Ｐ＜０．０５,ｎ＝６）．（３）在ＫＣＩ（８０ｍＭ）使血管床收缩的基础上,Ｃａ＋＋（４０ｍＭ）使之明显舒张,ＳＨＲ的舒张程度小于ＷＫＹ约１５．０７％（Ｆ＜０．０５,ｎ＝６）。     

Effect of an ACE inhibitor and an AT1 receptor antagonist on cardiac hypertrophy

The effect of long-term administration of delapril, an angiotensin converting enzyme inhibitor, and candesartan, an angiotensin II receptor blocker, on cardiac hypertrophy was investigated in spontaneously hypertensive rats (SHR). Delapril (2 mg/kg/day) and candesartan (2 mg/kg/day) were administered for 5 weeks to 15-week-old male SHR. Echocardiographic estimation of cardiac morphology and function revealed cardiac hypertrophy in SHR compared with Wistar-Kyoto rats (WKY) which were used as normal controls. Both treated groups revealed regression of cardiac hypertrophy estimated by echocardiography. Heart to body weight ratio of treated SHR was also smaller than that of untreated SHR. Plasma BNP and ANP concentrations were increased in untreated SHR and decreased in the treated groups. Histological examination was performed using light microscopy and the area of fibrosis was estimated by computer. Reduction of the fibrotic area was observed in SHR treated with delapril and candesartan, although the latter was not statistically significant. Immunohistochemical examination using anti-collagen monoclonal antibody showed a decrease of type I collagen in treated SHR as compared with untreated SHR. It is concluded that both angiotensin converting enzyme inhibitor and angiotensin II receptor blocker sufficiently reduce blood pressure in SHR associated with regression of cardiac remodeling.     

Single-cell RNA analysis on ACE2 expression provides insights into SARS-CoV-2 potential entry into the bloodstream and heart injury

Coronavirus disease-2019 (COVID-19) is a global pandemic with high infectivity and pathogenicity, accounting for tens of thousands of deaths worldwide. Recent studies have found that the pathogen of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), shares the same cell receptor angiotensin converting enzyme II (ACE2) as SARS-CoV. The pathological investigation of COVID-19 deaths showed that the lungs had characteristics of pulmonary fibrosis. However, how SARS-CoV-2 spreads from the lungs to other organs has not yet been determined. Here, we performed an unbiased evaluation of cell-type-specific expression of ACE2 in healthy and fibrotic lungs, as well as in normal and failed adult human hearts, using published single-cell RNA-seq data. We found that ACE2 expression in fibrotic lungs mainly locates in arterial vascular cells, which might provide a route for bloodstream spreading of SARS-CoV-2. Failed human hearts have a higher percentage of ACE2-expressing cardiomyocytes, and SARS-CoV-2 might attack cardiomyocytes through the bloodstream in patients with heart failure. Moreover, ACE2 was highly expressed in cells infected by respiratory syncytial virus or Middle East respiratory syndrome coronavirus and in mice treated by lipopolysaccharide. Our findings indicate that patients with pulmonary fibrosis, heart failure, and virus infection have a higher risk and are more susceptible to SARS-CoV-2 infection. The SARS-CoV-2 might attack other organs by getting into the bloodstream. This study provides new insights into SARS-CoV-2 blood entry and heart injury and might propose a therapeutic strategy to prevent patients from developing severe complications.     

SHR与WKY大鼠肾脏组织基因表达差异分析

为了观察SHR与WKY大鼠肾脏组织的基因表达的差异,用T11G、AP6引物对12周龄的SHR与WKY大鼠肾脏mRNA进行了差异显示,得到了一条在SHR大鼠肾脏组织中高表达的差异显示条带,进一步分析证明这一差异显示条带含有170 bp,与GenBank 收录的已知的核苷酸序列的同源性低于80%,可能为未知基因的cDNA片段,并定位于SHR大鼠的肾小管上皮细胞内.     

The role of SARS-CoV-2 target ACE2 in cardiovascular diseases

SARS-CoV-2, the virus responsible for the global coronavirus disease (COVID-19) pandemic, attacks multiple organs of the human body by binding to angiotensin-converting enzyme 2 (ACE2) to enter cells. More than 20 million people have already been infected by the virus. ACE2 is not only a functional receptor of COVID-19 but also an important endogenous antagonist of the renin-angiotensin system (RAS). A large number of studies have shown that ACE2 can reverse myocardial injury in various cardiovascular diseases (CVDs) as well as is exert anti-inflammatory, antioxidant, anti-apoptotic and anticardiomyocyte fibrosis effects by regulating transforming growth factor beta, mitogen-activated protein kinases, calcium ions in cells and other major pathways. The ACE2/angiotensin-(1-7)/Mas receptor axis plays a decisive role in the cardiovascular system to combat the negative effects of the ACE/angiotensin II/angiotensin II type 1 receptor axis. However, the underlying mechanism of ACE2 in cardiac protection remains unclear. Some approaches for enhancing ACE2 expression in CVDs have been suggested, which may provide targets for the development of novel clinical therapies. In this review, we aimed to identify and summarize the role of ACE2 in CVDs.     

ACE、CYP11B2基因多态性与慢性心力衰竭患者醛固酮脱逸的关系

目的:研究CYP11B2-344C/T(醛固酮合成酶)及ACEI/D(血管紧张素转化酶)基因多态性与慢性心力衰竭(CHF)患者实施ACEI治疗后出现醛固酮脱逸表现的关系。方法:回顾分析2008年10月至2012年10月我科收治的252例CHF患者,全部患者应用ACEI治疗3月,醛固酮在基线以上为醛固酮脱逸,依据此标准将患者分为研究组(脱逸组,n=86)与对照组(非脱逸组,n=166),依据PCR(聚合酶链反应)及RFLP(片段长度限制多态性)等方法分别检测两组CYP11B2及ACE基因型,比较两组基因型频率的分布。结果:252例患者中,共86例出现醛固酮脱逸,发生率为34.1%。全部受试患者CYP11B2基因型及ACE基因型频率与Weinberg-Hardy平衡均相符(P均0.05)。研究组ACE I/D三种基因型的组间分布与对照组相较,无统计学差异(P0.05);CYP11B2基因TT型的频率与对照组相较,呈明显统计学差异(P0.05),等位基因C/T频率的组间分布同对照组相较,亦呈明显差异(P0.05)。研究组ACEI/D的基因多态性及CYP11B2-344C/T的多态性中,基因型联合组间分布与对照组相较,无统计学差异(P0.05)。结论:ACE基因多态性与CHF患者ACEI治疗后出现醛固酮脱逸无关,CYP11B2基因T等位基因及TT基因型多态性可能是CHF患者ACEI治疗后发生醛固酮脱逸的高危因素。醛固酮脱逸时,ACE、CYP11B2基因不具有协同效果。     

Downregulation of ACE2 expression by SARS-CoV-2 worsens the prognosis of KIRC and KIRP patients via metabolism and immunoregulation

Background: Angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) allow entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into host cells and play essential roles in cancer therapy. However, the functions of ACE2 and TMPRSS2 in kidney cancer remain unclear, especially as kidneys are targets for SARS-CoV-2 infection.Methods: UCSC Xena project, the Cancer Genome Atlas (TCGA), and Gene Expression Omnibus (GEO) databases ({"type":"entrez-geo","attrs":{"text":"GSE30589","term_id":"30589"}}GSE30589 and {"type":"entrez-geo","attrs":{"text":"GSE59185","term_id":"59185"}}GSE59185) were searched for gene expression in human tissues, gene expression data, and clinical information. Several bioinformatics methods were utilized to analyze the correlation between ACE2 and TMPRSS2 with respect to the prognosis of kidney renal clear cell carcinoma (KIRC) and kidney renal papillary cell carcinoma (KIRP).Results: ACE2 expression was significantly upregulated in tumor tissue, while its downregulation was associated with low survival in KIRC and KIRP patients. TMPRSS2 was downregulated in KIRC and KIRP, and its expression was not correlated with patient survival. According to clinical risk factor-based prediction models, ACE2 exhibits predictive accuracy for kidney cancer prognosis and is correlated with metabolism and immune infiltration. In an animal model, ACE2 expression was remarkably downregulated in SARS-CoV-2-infected cells compared to in the control.Conclusion: ACE2 expression is highly correlated with various metabolic pathways and is involved in immune infiltration.it plays a crucial role than TMPRSS2 in diagnosing and prognosis of kidney cancer patients. The overlap in ACE2 expression between kidney cancer and SARS-CoV-2 infection suggests that patients with KIRC or KIRP are at high risk of developing serious symptoms.     

Subtle Influence of ACE2 Glycan Processing on SARS-CoV-2 Recognition

The severity of SARS-CoV-2 infection is highly variable and yet the molecular basis for this effect remains elusive. One potential contribution are differences in the glycosylation of target human cells, particularly as SARS-CoV-2 has the capacity to bind sialic acid which is a common, and highly variable, terminal modification of glycans. The viral spike glycoprotein (S) of SARS-CoV-2 and the human cellular receptor, angiotensin-converting enzyme 2 (ACE2) are both densely glycosylated. We therefore sought to investigate whether the glycosylation state of ACE2 impacts the interaction with SARS-CoV-2 viral spike. We generated a panel of engineered ACE2 glycoforms which were analyzed by mass spectrometry to reveal the site-specific glycan modifications. We then probed the impact of ACE2 glycosylation on S binding and revealed a subtle sensitivity with hypersialylated or oligomannose-type glycans slightly impeding the interaction. In contrast, deglycosylation of ACE2 did not influence SARS-CoV-2 binding. Overall, ACE2 glycosylation does not significantly influence viral spike binding. We suggest that any role of glycosylation in the pathobiology of SARS-CoV-2 will lie beyond its immediate impact of receptor glycosylation on virus binding.